Stockreport

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 MARSEILLE, France--(BUSINESS WIRE)--Regulatory [Read more]